State-level insulin cost caps ineffective in increasing insulin use among diabetes patients

FHS
August 5, 2024
11:29 am

In a first-of-its-kind study, a cohort of researchers, led by the University of Colorado Anschutz Medical Campus, evaluated the effects of state-level insulin out-of-pocket costs across states and payers and over time.

Sanofi shakes up clinical plans for trio of programs from Denali, Principia and Kymab deals

Sanofi is shuffling its pipeline after several trial flops in anti-inflammatory and cancer drugs it landed through a partnership with Denali and buyouts of Principia

October 28, 2023

Alto Neuroscience closes $45M round; Simcere partners with Connect; Myricx licenses WuXi antibody

Neuroscience company closes $45M round: Alto Neuroscience closed an oversubscribed $45 million Series C, led by InVivium Capital, it announced Tuesday. New investors included Franklin

November 22, 2023

What the Sarepta decision means for Duchenne patients, the company, and the FDA

Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on

June 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.